Transcenta Says Regulators Approve Osemitamab Global Phase III Trial
Transcenta says regulators in the U.S., China and South Korea approved a global Phase III trial of osemitamab.
Transcenta says regulators in the U.S., China and South Korea approved a global Phase III trial of osemitamab.